Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul W Sperduto

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
International Journal of Radiation Oncology, Biology, Physics|February 9, 2013
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320Paul W Sperduto, Meihua Wang, H Ian Robins, et al.
Advances in Radiation Oncology|July 2, 2026
Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain MetastasesJim X Leng, Muzamil Arshad, David J Carpenter, et al.
Neuro-Oncology Practice|November 18, 2024
Validation of the graded prognostic assessment and recursive partitioning analysis as prognostic tools using a modern cohort of patients with brain metastasesJacob Sperber, Seeley Yoo, Edwin Owolo, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2009
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patientsPaul W Sperduto, Samuel T Chao, Penny K Sneed, et al.
Journal of Neuro-Oncology|August 23, 2018
Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation studyStephanie R Rice, Søren M Bentzen, Andrew Hanna, et al.
The Lancet. Oncology|November 27, 2025
Neurocognitive outcomes in patients with brain metastases: a systematic reviewTarek Bou Dargham, Sebastian F Winter, Kristen Batich, et al.
Journal of Neuro-Oncology|March 7, 2013
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancerPaul W Sperduto, Norbert Kased, David Roberge, et al.
BMC Cancer|February 14, 2020
Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)Anna Patrikidou, Loic Chaigneau, Nicolas Isambert, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2017
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)Paul W Sperduto, Wen Jiang, Paul D Brown, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2017
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain MetastasesPaul W Sperduto, Wen Jiang, Paul D Brown, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|February 9, 2013
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320Paul W Sperduto, Meihua Wang, H Ian Robins, et al.
Advances in Radiation Oncology|July 2, 2026
Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain MetastasesJim X Leng, Muzamil Arshad, David J Carpenter, et al.
Neuro-Oncology Practice|November 18, 2024
Validation of the graded prognostic assessment and recursive partitioning analysis as prognostic tools using a modern cohort of patients with brain metastasesJacob Sperber, Seeley Yoo, Edwin Owolo, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2009
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patientsPaul W Sperduto, Samuel T Chao, Penny K Sneed, et al.
Journal of Neuro-Oncology|August 23, 2018
Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation studyStephanie R Rice, Søren M Bentzen, Andrew Hanna, et al.
The Lancet. Oncology|November 27, 2025
Neurocognitive outcomes in patients with brain metastases: a systematic reviewTarek Bou Dargham, Sebastian F Winter, Kristen Batich, et al.
Journal of Neuro-Oncology|March 7, 2013
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancerPaul W Sperduto, Norbert Kased, David Roberge, et al.
BMC Cancer|February 14, 2020
Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)Anna Patrikidou, Loic Chaigneau, Nicolas Isambert, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2017
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)Paul W Sperduto, Wen Jiang, Paul D Brown, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2017
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain MetastasesPaul W Sperduto, Wen Jiang, Paul D Brown, et al.
Pageof 5